A Superiority Study of LY248686 [duloxetine] Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain.

Trial Profile

A Superiority Study of LY248686 [duloxetine] Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2011

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Mar 2011 Actual end date of the extension trial (NCT00641719) is Mar 2010.
    • 30 Mar 2011 Actual end date of the extension trial (NCT00641719) is Mar 2010.
    • 30 Mar 2011 Actual start date of the extension trial (NCT00641719) is Mar 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top